Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Rating Upgraded by ValuEngine
08:50am, Wednesday, 01'st Apr 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday, ValuEngine reports. KNSA has been the subject of se
Kiniksa Pharmaceuticals (KNSA) - Research Analysts' Recent Ratings Updates
08:24am, Wednesday, 01'st Apr 2020
Kiniksa Pharmaceuticals (NASDAQ: KNSA) has recently received a number of price target changes and ratings updates: 3/30/2020 – Kiniksa Pharmaceuticals was upgraded by analysts at ValuEngine from a �
Afternoon Market Stats in 5 Minutes
04:57pm, Tuesday, 31'st Mar 2020
Movers Indices • S&P 500 ETF (NYSE:SPY) rose 0.53% to $262.95.• Nasdaq ETF (NASDAQ:QQQ) rose 1.22% to $194.38.• Dow Jones Industrial Average ETF (NYSE:DIA) rose 0.61% to $224.32.• FTSE/Xinhua
56 Stocks Moving In Tuesday's Mid-Day Session
04:27pm, Tuesday, 31'st Mar 2020
Gainers
SG Blocks, Inc. (NASDAQ: SGBX) shares climbed 113.6% to $4.40 after the company reported Q4 results.
IZEA Worldwide, Inc. (NASDAQ: IZEA) jumped 41% to $0.2650 following...
HAL, APA among premarket gainers
01:17pm, Tuesday, 31'st Mar 2020
SG Blocks (NASDAQ:SGBX) +100% on Q4 results.EyeGate Pharmaceuticals (NASDAQ:EYEG) +51% on positive dry eye data.Kiniksa Pharmaceuticals (NASDAQ:KNSA) +39% as mavrilimumab shows treatment response i
Covid-19-related announcements - healthcare
01:13pm, Tuesday, 31'st Mar 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) announces "early evidence" of treatment response in COVID-19-related pneumonia and hyperinflammation with antibody mavrilimumab. Shares up 42% premarket.V
Kiniksa Pharmaceuticals Ltd:
Kiniksa Pharma's mavrilimumab shows treatment response in COVID-19 patients; shares up 39% premarket
12:39pm, Tuesday, 31'st Mar 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) announces early evidence of treatment response with mavrilimumab, an investigational fully-human monoclonal antibody, in a treatment protocol in patients with se
The treatment protocol was conducted by Professor Lorenzo Dagna, MD, FACP, Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute Sa
Kiniksa Pharmaceuticals Ltd:
- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment.
Charles Schwab Investment Management Inc. Sells 5,964 Shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
08:18am, Monday, 23'rd Mar 2020
Charles Schwab Investment Management Inc. lowered its position in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 16.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor own
Contrasting Immunic (NASDAQ:IMUX) and Kiniksa Pharmaceuticals (NASDAQ:KNSA)
05:32am, Monday, 23'rd Mar 2020
Immunic (NASDAQ:IMUX) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their
Contrasting Ionis Pharmaceuticals (NASDAQ:IONS) and Kiniksa Pharmaceuticals (NASDAQ:KNSA)
10:16am, Sunday, 22'nd Mar 2020
Ionis Pharmaceuticals (NASDAQ:IONS) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength o
Alyeska Investment Group L.P. Grows Stake in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
08:40am, Friday, 20'th Mar 2020
Alyeska Investment Group L.P. boosted its position in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 6.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commiss
